PACTR201105000289276已完成未知
Phase II double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of H1/IC31 (trademarked), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells per mm cubed
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- All
入选标准
- •1. TB negative
- •2. HIV infected
- •3. CD4 count greater than 350 cells per ml cubed
排除标准
- •Evidence of or suspected active TB
研究者
相似试验
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.EUCTR2018-002547-29-FRAtox Bio120
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.Acute kidney injury due to intra-abdominal infection/sepsisMedDRA version: 20.1Level: LLTClassification code 10080269Term: Stage 2 acute kidney injurySystem Organ Class: 100000004857MedDRA version: 20.1Level: LLTClassification code 10080271Term: Stage 3 acute kidney injurySystem Organ Class: 100000004857MedDRA version: 20.1Level: LLTClassification code 10079983Term: Complicated intra-abdominal infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10040050Term: Sepsis NOSSystem Organ Class: 100000004862EUCTR2018-002547-29-BEAtox Bio120
进行中（未招募）
1 期
This is a Phase 2 randomized, double-blind study to determine the safety and efficacy of Reltecimod as compared to placebo in patients who have acute kidney injury due to an intra-abddominal infection causing sepsis in which all patients receive usual standard of care treatment for their infection.EUCTR2018-002547-29-NLAtox Bio120
尚未招募
2 期
Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with sepsis-associated acute kidney injury (SA-AKI)NL-OMON48294Atox Bio Ltd.12
已完成
不适用
Phase II randomised, double-blind, placebo controlled, multicentre study of orally administered ATL-104 (by swallowable mouthwash) to assess safety and tolerance and effect on oral mucositis in patients with haematological malignancies after treatment with chemotherapy associated with peripheral blood stem cell transplant (PBSCT)ISRCTN68967559Alizyme (UK)60